Previous close | 0.2000 |
Open | 0.1900 |
Bid | 0.2000 |
Ask | 0.2500 |
Strike | 2.00 |
Expiry date | 2024-07-19 |
Day's range | 0.1500 - 0.2000 |
Contract range | N/A |
Volume | |
Open interest | 3.04k |
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.